PPD clinical research business of Thermo Fisher Scientific

What PPD clinical research business of Thermo Fisher Scientific does

PPD is the clinical research business of Thermo Fisher Scientific, operating as a global full-service Contract Research Organization (CRO) that delivers end-to-end drug development services across Phase I-IV clinical trials, bioanalytical and central laboratory services, real-world evidence generation, and language solutions. Founded in 1985, PPD serves pharmaceutical and biopharmaceutical companies as its primary customer base, alongside biotechnology firms, medical device manufacturers, government and public health organizations, and academic institutions, with named customers including Moderna, Novavax, Takeda, and argenx. The business operates from a Waltham, Massachusetts headquarters with 35,000+ employees across 45+ countries and clinical trial experience spanning more than 100 countries.

PPD's core technology platforms include Preclarus, an award-winning clinical trial data and analytics platform covering more than 180,000 investigator sites in over 100 countries and 5,000+ studies; TrueCast, an AI-powered predictive analytics engine trained on data from 26,000+ clinical trials and nearly 8 million patients; PPD OncoLocator providing treatment data for 25 cancers; and PPD Translate, an AI-enhanced language services platform supporting 300+ language pairs and 80,000+ projects per year. The Accelerator Drug Development platform integrates CRO and CDMO capabilities under the Thermo Fisher umbrella. Proprietary real-world evidence assets include the CorEvitas clinical registries (Alzheimer's, obesity, chronic hand eczema, dermatology, neurology) and Vestrum Health.

The business generates revenue primarily through professional services engagements priced on a project, FTE, unit-based, time-and-materials, or hybrid basis across full-service clinical development, Functional Service Partnership (FSP) models, laboratory services, and real-world evidence contracts. PPD was acquired by Thermo Fisher Scientific in 2021 for approximately $17.4 billion and is now integrated within the parent's life sciences solutions segment; standalone revenue exceeded $4 billion in 2019 prior to acquisition.

Name

PPD clinical research business of Thermo Fisher Scientific

Legal name

PPD clinical research business of Thermo Fisher Scientific

Website

https://ppd.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PPD is the global clinical research business of Thermo Fisher Scientific, delivering full-service CRO capabilities across Phase I-IV trials, laboratory services, real-world evidence, and AI-enabled data platforms to pharmaceutical, biotech, medical device, and government clients worldwide.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Laboratory services
• Real-world evidence

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Development Services: Full-service Phase I-IV clinical trial management including study design, protocol development, site management, monitoring, data management, biostatistics, and regulatory affairs.
2. Laboratory Services: Comprehensive laboratory services including bioanalytical labs, central labs, GMP labs, biomarker solutions, vaccine sciences labs, and central laboratory services supporting clinical trials globally.
3. Real-World Evidence and Health Economics: Evidence-based solutions including health economics models, market access, patient-centered research, observational studies, and real-world data registries (CorEvitas, Vestrum Health).
4. Functional Service Partnership (FSP) Solutions: Flexible staffing and functional outsourcing models providing dedicated teams for specific functional areas including biostatistics, clinical data management, pharmacovigilance, regulatory affairs, project delivery, and feasibility.
5. PPD Translate Solutions: Translation and localization services for clinical trials and pharmaceutical companies, supporting regulatory submissions, labeling, packaging, and multilingual clinical documentation.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

PPD operates as a global Contract Research Organization (CRO) delivering end-to-end Phase I-IV clinical trial management, bioanalytical and central laboratory services, real-world evidence generation, health economics and market access support, regulatory affairs, pharmacovigilance, and translation services for pharmaceutical, biotechnology, medical device, academic, and government clients. The business combines proprietary data and analytics platforms (Preclarus, TrueCast, PPD Translate) with a global site network spanning 45+ countries, and integrates with Thermo Fisher Scientific's CDMO capabilities through the Accelerator Drug Development platform.

Product overview

PPD clinical research business of Thermo Fisher Scientific operates as a comprehensive CRO solutions provider offering integrated drug development services across the pharmaceutical development lifecycle. The portfolio combines the core Preclarus data and analytics platform with specialized solutions including PPD CorEvitas real-world evidence registries (Clinical Registries, Precision Medicine, Vestrum Health), PPD Translate language services, and PPD Evidera health economics and market access capabilities. Laboratory services encompass bioanalytical, central, GMP, vaccine sciences, and biomarker labs. Clinical services span Phase I-IV trial management, pharmacovigilance, biostatistics, regulatory affairs, and real-world evidence generation. Delivery models include traditional full-service CRO, Functional Service Partnership (FSP) solutions, and biotech-specific solutions, all supported by AI-powered digital tools including Clinical Decision Suite and Clinical Trial Forecasting Suite. The integrated Accelerator Drug Development platform combines CRO and CDMO capabilities for seamless development-to-manufacturing pathways.

Differentiator

Problem solved

Functional benefit

Brands

• PPD CorEvitas: Regulatory-grade real-world evidence registry and data solutions
• PPD Evidera
• PPD Translate
• Preclarus
• Accelerator Drug Development
• PPD-SNBL

Products and services

• Preclarus
• PPD Translate Solutions
• PPD CorEvitas Clinical Registries
• Accelerator Drug Development
• PPD Bioanalytical Lab
• PPD Central Lab
• PPD GMP Lab
• PPD Vaccine Sciences Lab
• PPD Biomarker Lab
• PPD FSP (Functional Service Partnership) Solutions
• PPD Biotech Solutions
• PPD Patient First Digital Solutions
• PPD CorEvitas Precision Medicine
• PPD Vestrum Health Real-World Data
• Clinical Decision Suite
• Clinical Trial Forecasting Suite
• PPD Evidera Health Economics
• PPD Evidera Market Access
• PPD Evidera Patient-Centered Research
• PPD Evidera Implementation Science

Quantifiable outcome

• Reduced placebo response by up to 22% when site personnel and subjects are properly trained
• +4 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability12 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• HealthVeritycoreTechnology or Integration · 13 April 2026PPD collaborated with HealthVerity in April 2026 to expand real-world data capabilities. The collaboration enhances PPD's ability to access and integrate diverse real-world data sources for clinical research and evidence generation.
• DatavantcoreTechnology or Integration · 11 February 2026Thermo Fisher Scientific expanded real-world data interoperability and linkage through strategic collaboration with Datavant in February 2026. This partnership strengthens data connectivity capabilities for PPD's real-world evidence services.
• CorEvitascoreStrategic or Co-development Partner · 1 January 2023Thermo Fisher Scientific acquired CorEvitas in 2023, establishing PPD as a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies. CorEvitas provides clinical registries and real-world data supporting post-market surveillance and evidence generation.
• PPD-SNBL (Shin Nihon) Joint VenturecoreStrategic or Co-development Partner · 1 January 2014PPD formed PPD-SNBL joint venture in 2014 with Shin Nihon (now part of SNBL) to provide full range of clinical development services in Japan. PPD-SNBL is one of the largest clinical development service providers in Japan.
• One Tree PlantedminorStrategic or Co-development PartnerPPD partners with One Tree Planted, a nonprofit focused on global reforestation, to plant a tree for every patient enrolled at one of PPD's sites. Partnership supports environmental sustainability and carbon sequestration initiatives.
• Pistoia AllianceminorStrategic or Co-development PartnerPPD engages with the Pistoia Alliance in a cross-industry partnership to understand activity-based models to reduce carbon footprint in clinical trials.
• United Airlines Eco-Skies AllianceminorStrategic or Co-development PartnerPPD partners with United Airlines Eco-Skies Alliance supporting the use of aviation biofuel and sustainable travel options for clinical trial operations.
• TakedaminorStrategic or Co-development PartnerPPD entered a research collaboration with Takeda for preclinical research as mentioned in market developments.

Scale indicators17 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Syneos Health: Now private (Elliott/Veritas/Patient Square), Syneos is a biopharma solutions organization offering clinical development and commercialization services. It is a comparable full-service CRO competing for both pharma and biotech trials.
• Parexel International: Private-equity-owned global CRO (EQT/Goldman Sachs) offering biopharma clinical development, real-world evidence, and regulatory services. Competes with PPD across enterprise pharma and biotech accounts.
• ICON plc: Post-PRA Health Sciences acquisition, ICON is one of the two largest pure-play CROs globally, with comparable Phase I-IV, labs, FSP and biotech offerings. It competes head-to-head with PPD for large pharma and biotech mandates.
• Fortrea: Spun out from Labcorp as its clinical development and commercialization services business. Fortrea offers Phase I-IV CRO services, central labs and patient access, competing with PPD across most enterprise clinical development categories.
• Medpace Holdings: A faster-growing, mid-sized full-service CRO focused primarily on small and mid-sized biotech sponsors. Medpace competes with PPD's biotech solutions and FSP businesses, particularly in oncology and rare disease trials.
• IQVIA: The largest global CRO and clinical technology provider, offering full-service clinical development, real-world evidence, and analytics. IQVIA is PPD's most direct full-service competitor across Phase I-IV trials, labs, and data-driven trial design.
• Charles River Laboratories: Provides preclinical and clinical CRO services plus manufacturing support. Overlaps with PPD in clinical development and adjacent lab/CDMO services, particularly for early-phase and safety assessment work.

Broad incumbents

• Thermo Fisher Scientific (CDMO / PPD parent): PPD's parent company, whose pharma services segment (Patheon CDMO, clinical packaging, bioanalytical labs) provides integrated CDMO and analytical services that complement PPD's CRO offerings through the Accelerator Drug Development platform.

Emerging players

• Labcorp (Central Labs & Early Development): Retained central lab and early development business after the Fortrea spin. Competes with PPD's bioanalytical and central laboratory services for clinical-trial sample testing and specialty lab work.

Regional players

• WuXi AppTec / WuXi Clinical: China-headquartered CRO/CDMO with growing global clinical development footprint. Competes with PPD on cost-competitive Asia-based trial conduct and lab services, particularly for sponsors with significant China trial programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/ppdcro
• YouTubeyoutube.com/PPDCRO
• Facebookfacebook.com/PPDCRO
• LinkedInlinkedin.com/company/ppd
• Instagraminstagram.com/ppdcro

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries8 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments8 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PPD clinical research business of Thermo Fisher Scientific